-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Videos|November 6, 2016

Andrei Gonzales Discusses Struggles of Move to Value-Based Care

As the healthcare system adjusts to the transition to value-based care, providers in particular are having a hard time keeping up with all of the changes, said Andrei Gonzales, director of value-based reimbursement initiatives at McKesson Health Solutions.

As the healthcare system adjusts to the transition to value-based care, providers in particular are having a hard time keeping up with all of the changes, said Andrei Gonzales, director of value-based reimbursement initiatives at McKesson Health Solutions.

Transcript (slightly modified)

What remains the biggest hurdle facing the US in the move to value-based care?

I’d say the biggest hurdle is the transition from the current fee-for-service structure, to a value-based reimbursement structure. The study that we did shows that providers are struggling, and they are lagging payers in their progression towards value-based reimbursement.

And you know, providers have a very busy job right now just to take care of their patients, and the transition requires a lot of work in terms of building care coordination capabilities, in terms of building data integration so that all the different stakeholders in the continuum of care really understand what’s happening for their patients in these value-based models and understand where opportunities for improvement are, and to be able to make those changes to really see the improvements that they’re looking for. So that transition is going to be a very heavy lift; it has been and it’s going to continue to be until we reach more of a steady state and gone through this transition phase.


Related to this article

Anthony Stein, MD | Image: City of Hope
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.